ATE469650T1 - Verwendung von megestrolacetat zur verbesserung der herzfunktion und zur behandlung von herzinsuffizienz - Google Patents

Verwendung von megestrolacetat zur verbesserung der herzfunktion und zur behandlung von herzinsuffizienz

Info

Publication number: ATE469650T1
Authority: AT; Austria
Prior art keywords: megestrol acetate; improve; heart; treat; heart failure
Prior art date: 2004-12-01

Application number

AT04028474T

Other languages

English (en)

Inventor

Stefan Anker

Original Assignee

Par Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-01

Filing date

2004-12-01

Publication date

2010-06-15

2004-12-01 Application filed by Par Pharmaceuticals Inc filed Critical Par Pharmaceuticals Inc

2010-06-15 Application granted granted Critical

2010-06-15 Publication of ATE469650T1 publication Critical patent/ATE469650T1/de

Links

206010019280 Heart failures Diseases 0.000 title abstract 3
RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 title abstract 3
230000004217 heart function Effects 0.000 title abstract 2
229960004296 megestrol acetate Drugs 0.000 title abstract 2
229940090004 megace Drugs 0.000 abstract 1
208000010125 myocardial infarction Diseases 0.000 abstract 1
230000004083 survival effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Dispersion Chemistry (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Saccharide Compounds (AREA)

AT04028474T 2004-12-01 2004-12-01 Verwendung von megestrolacetat zur verbesserung der herzfunktion und zur behandlung von herzinsuffizienz ATE469650T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP04028474A EP1669074B1 (de)	2004-12-01	2004-12-01	Verwendung von Megestrolacetat zur Verbesserung der Herzfunktion und zur Behandlung von Herzinsuffizienz

Publications (1)

Publication Number	Publication Date
ATE469650T1 true ATE469650T1 (de)	2010-06-15

Family

ID=34927608

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04028474T ATE469650T1 (de)	2004-12-01	2004-12-01	Verwendung von megestrolacetat zur verbesserung der herzfunktion und zur behandlung von herzinsuffizienz

Country Status (9)

Country	Link
US (3)	US8383612B2 (de)
EP (2)	EP1669074B1 (de)
AT (1)	ATE469650T1 (de)
DE (1)	DE602004027515D1 (de)
DK (1)	DK1669074T3 (de)
ES (2)	ES2346755T3 (de)
PL (1)	PL1863492T3 (de)
SI (1)	SI1669074T1 (de)
WO (1)	WO2006058748A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8119137B2 (en)	2004-12-23	2012-02-21	Csl Behring Gmbh	Prevention of thrombus formation and/or stabilization with inhibitors of factor XII or activated factor XII
WO2009071405A1 (en) *	2007-12-04	2009-06-11	Charité - Universitätsmedizin Berlin	Megestrol acetate for reducing the mortality and/or improving quality of life in cancer patients
US10334873B2 (en) *	2016-06-16	2019-07-02	Altria Client Services Llc	Breakable capsules and methods of forming thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4370321A (en) *	1976-09-01	1983-01-25	Mead Johnson And Company	Progestational adjuvant therapy
US5144017A (en) *	1988-07-13	1992-09-01	University Of Manitoba	Compounds that bind to digitalis receptor
SE9600046D0 (sv) *	1996-01-05	1996-01-05	Astra Ab	New pharmaceutical formulation
EP2263650A3 (de) *	2002-04-12	2013-12-25	Alkermes Pharma Ireland Limited	Nanopartikuläre Megestrol- Formulierungen
US7101576B2 (en)	2002-04-12	2006-09-05	Elan Pharma International Limited	Nanoparticulate megestrol formulations
PT1558265E (pt) *	2002-11-05	2010-03-22	Bayer Schering Pharma Ag	Utilização da drospirenona para o tratamento da hipertensão

2004
- 2004-12-01 DE DE602004027515T patent/DE602004027515D1/de not_active Expired - Lifetime
- 2004-12-01 AT AT04028474T patent/ATE469650T1/de not_active IP Right Cessation
- 2004-12-01 ES ES04028474T patent/ES2346755T3/es not_active Expired - Lifetime
- 2004-12-01 DK DK04028474.7T patent/DK1669074T3/da active
- 2004-12-01 SI SI200431485T patent/SI1669074T1/sl unknown
- 2004-12-01 EP EP04028474A patent/EP1669074B1/de not_active Expired - Lifetime
2005
- 2005-12-01 US US11/667,899 patent/US8383612B2/en not_active Expired - Fee Related
- 2005-12-01 WO PCT/EP2005/012843 patent/WO2006058748A1/en not_active Ceased
- 2005-12-01 PL PL05814628T patent/PL1863492T3/pl unknown
- 2005-12-01 ES ES05814628T patent/ES2423944T3/es not_active Expired - Lifetime
- 2005-12-01 EP EP05814628.3A patent/EP1863492B1/de not_active Expired - Lifetime
2013
- 2013-01-17 US US13/743,463 patent/US20130143848A1/en not_active Abandoned
2015
- 2015-12-02 US US14/956,907 patent/US20160101117A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PL1863492T3 (pl)	2013-10-31
ES2346755T3 (es)	2010-10-20
WO2006058748A1 (en)	2006-06-08
US20160101117A1 (en)	2016-04-14
ES2423944T3 (es)	2013-09-25
EP1669074B1 (de)	2010-06-02
EP1863492B1 (de)	2013-05-08
EP1863492A1 (de)	2007-12-12
US20130143848A1 (en)	2013-06-06
DK1669074T3 (da)	2010-09-27
SI1669074T1 (sl)	2010-10-29
US20080139521A1 (en)	2008-06-12
DE602004027515D1 (de)	2010-07-15
US8383612B2 (en)	2013-02-26
EP1669074A1 (de)	2006-06-14

Similar Documents

Publication	Publication Date	Title
NO20070257L (no)	2007-01-16	Forbindelser, blandinger og metoder
DE602006007093D1 (de)	2009-07-16	Kombinationstherapie zur Behandlung von Diabetes und dadurch bedingten Leiden sowie zur Behandlung von mittels Erhöhung des GLP-1-Spiegels im Blut verbesserten Leiden
NO20074943L (no)	2007-10-01	Roflumilast for behandlingen av diabetes mellitus
MXPA02007639A (es)	2004-08-23	Inhibidores de la oxidacion parcial de los acidos grasos en el tratamiento de la falla cardiaca congestiva.
MX2007007781A (es)	2007-08-22	Composiciones cardiovasculares.
WO2006068729A3 (en)	2007-01-18	Methods and compositions for enhancing iron absorption
ATE534747T1 (de)	2011-12-15	1l1rl-1 als marker für kardiovaskuläre erkrankungen
ATE355852T1 (de)	2007-03-15	Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
EA200900392A1 (ru)	2010-06-30	Комбинированное лечение сахарного диабета
NO20076121L (no)	2008-02-04	Behandlinger for kardiovaskulaer sykdom
DE602008004643D1 (de)	2011-03-03	1-ä2-(2,4-dimethylphenylsulfanyl)phenylüpiperazin als verbindung mit kombinierter serotonin-aufnahme, 5-ht3- und 5-ht1a-aktivität zur behandlung von schmerzen oder restsymptomen bei depressionen im zusammenhang mt schlaf und kognition
ATE542536T1 (de)	2012-02-15	3-ä4-(dibenzoäb,füä1,4üoxazepin-11-yl)-piperazi - 1-ylü-2,2-dimethyl propansäure zur verwendung in der behandlung von schlafstörungen
ATE359087T1 (de)	2007-05-15	Verwendung von erythropoietin zur behandlung oder vorbeugung von herzversagen
DE60335647D1 (de)	2011-02-17	Pyrroloquinoline quinone und ein betablocker zur behandlung von ischämie oder reperfusionsschäden
ATE464895T1 (de)	2010-05-15	Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von depressionen
ATE501718T1 (de)	2011-04-15	Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von manie und bipolaren störungen
ATE400297T1 (de)	2008-07-15	Ctgf als zielmolekül in der behandlung von mikroalbuminurie in patienten mit diabetischer nephropathie
WO2006114105A3 (en)	2007-05-18	Use of modified factor vii for treating bleeding
MXPA02004598A (es)	2004-09-10	Compuestos novedosos para tratar diabetes y condiciones asociadas.
ATE469650T1 (de)	2010-06-15	Verwendung von megestrolacetat zur verbesserung der herzfunktion und zur behandlung von herzinsuffizienz
DE602004010691D1 (de)	2008-01-24	Verwendung von xenon mit hypothermie zur behandlung von neugeborenen-asphyxie
MX2008009161A (es)	2009-04-16	Tratamiento de enfermedad cardiovascular en mexicano-americanos, usando nebivolol.
DE602005013542D1 (de)	2009-05-07	Behandlung der oralen und darm mukositis durch verabreichung von menschlichem il-18
ATE449600T1 (de)	2009-12-15	Verwendung von glycerin zur verbesserung der herzfunktion
ATE525073T1 (de)	2011-10-15	Verwendung von pyrimidylaminobenzamiden zur behandlung von durch modulation einer tie-2 kinase-aktivität verursachten krankheiten

Legal Events

Date	Code	Title	Description
2010-12-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties